Bio-Techne(US:TECH)2026-03-03 17:12Bio-Techne Conference Call Summary Company Overview - Company: Bio-Techne - Industry: Life Sciences and Diagnostic Tools - Milestone: Celebrating 50th anniversary in 2026, established in 1976 in Minneapolis [4][3] Core Business and Growth Verticals - Bio-Techne has developed a portfolio of approximately 6,000 complex molecules, focusing on proteins and antibodies, which provides a competitive advantage [5] - The company has branched into four growth verticals: 1. Cell Therapy 2. Spatial Biology 3. Molecular Diagnostics 4. Core Reagents [6] Recent Performance - Fiscal 2Q Results: Total organic growth was flat, with underlying organic growth at approximately 3% [7] - Market Outlook: Confidence in achieving mid-single digit organic growth by the end of fiscal 2026, supported by strong performance in large pharma, which accounts for 30% of revenues [9][10] Market Dynamics - Large Pharma: Experienced double-digit growth for five consecutive quarters, indicating strong momentum [9] - Biotech Funding: Funding has improved significantly, with a 90% increase over the last four months, expected to positively impact life science tools [10] - Academic Market: Represents 22% of revenue, with ongoing bipartisan support for education and research funding [11] Growth Pillars - Cell and Gene Therapy: Currently a $80 million run rate, with $60 million from GMP proteins and $20 million from small molecules and media [22][24] - Wilson Wolf Acquisition: Expected to enhance the cell and gene therapy portfolio, with a focus on the G-Rex bioreactor technology [32][35] - Proteomic Analytical Tools: The ProteinSimple franchise has shown high single-digit growth, with consumables growing in double digits [37] Margin Expansion - Current Margins: Bio-Techne has maintained margins above 30% despite market challenges [44] - Future Outlook: Potential for 100 basis points of margin expansion with a return to double-digit growth across end markets [45] M&A Strategy - M&A has been a critical part of Bio-Techne's growth strategy, with 18 acquisitions in the last 10 years [50] - The company is open to further acquisitions to enhance its portfolio, particularly in cell therapy workflows and proteomic analytics [51] Conclusion - Bio-Techne is well-positioned for future growth with a strong portfolio, improving market conditions, and strategic acquisitions planned to enhance its capabilities in the life sciences sector [50][51]